Tobacco-Induced Neuronal Degeneration via Cotinine in Rats Subjected to Experimental Spinal Cord Injury

Abstract

Objectives Cigarette smoke contains over 4000 chemicals including well-characterized toxicants and carcinogens, among which is cotinine. Cotinine is the principal metabolite of nicotine that has adverse affects on the microcirculation via vasoconstriction, hypoxia and the wound-healing cascade. Its impact on spinal cord injury (SCI) has not been investigated yet. The aim of the present study is to investigate the cotinine effect on SCI.

Methods 48 male Wistar rats were divided into six groups as follows: sham-control, sham-trauma, vehicle-control, vehicle-trauma, cotinine-control, and cotinine-trauma. Initially, a defined concentration of cotinine blood level was maintained by daily intraperitoneal injection of cotinine for 14 days in the cotinine groups. The concentration was similar to the cotinine dose in the blood level of heavy smokers. Only ethyl alcohol was injected in the vehicle groups during the same period. Then, SCI was performed by a Tator clip. The cotinine groups were compared with rats subjected to vehicle and sham groups by immunohistochemical biomarkers such as glial fibrillary acidic protein (GFAP) and 2,3-cyclic nucleotide 3-phosphodiesterase (CNP) expressions. Electron microscopic examination was also performed.

Results GFAP-positive cells were noted to be localized around degenerated astrocytes. Marked vacuolization with perivascular and perineural edema was seen in the cotinin consumption groups. These findings showed the inhibition of regeneration after SCI. Similarly, vacuolization within myelin layers was noted in the cotinine groups, which was detected through reduced CNP expression.

Conclusion Cotinine, a main metabolite of nicotine, has harmful effects on SCI via GFAP and CNP expression. The findings of the present study support the hypothesis that tobacco causes neuronal degeneration via cotinine.

Keywords

tobacco - cotinine - neuronal degeneration - spinal cord injury

• References

• 1 Environmental Protection Agency. Respiratory health effects of passive smoking: lung cancer and other disorders. Washington, DC: 1992 : EPA Report/600/6–90/006F
• 2 Wong LS, Green HM, Feugate JE, Yadav M, Nothnagel EA, Martins-Green M. Effects of “second-hand” smoke on structure and function of fibroblasts, cells that are critical for tissue repair and remodeling. BMC Cell Biol 2004; 5: 13
• 3 Gori GB, Lynch CJ. Analytical cigarette yields as predictors of smoke bioavailability. Regul Toxicol Pharmacol 1985; 5 (3) 314-326
• 4 Hukkanen J, Jacob III P, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005; 57 (1) 79-115
• 5 Shields PG. Tobacco smoking, harm reduction, and biomarkers. J Natl Cancer Inst 2002; 94 (19) 1435-1444
• 6 Nusbaum ML, Gordon M, Nusbaum D, McCarthy MA, Vasilakis D. Smoke alarm: a review of the clinical impact of smoking on women. Prim Care Update Ob Gyns 2000; 7 (5) 207-214
• 7 Pauly JR, Slotkin TA. Maternal tobacco smoking, nicotine replacement and neurobehavioural development. Acta Paediatr 2008; 97 (10) 1331-1337
• 8 Ernst M, Moolchan ET, Robinson ML. Behavioral and neural consequences of prenatal exposure to nicotine. J Am Acad Child Adolesc Psychiatry 2001; 40 (6) 630-641
• 9 Winzer-Serhan UH. Long-term consequences of maternal smoking and developmental chronic nicotine exposure. Front Biosci 2008; 13: 636-649
• 10 Jauniaux E, Burton GJ. Morphological and biological effects of maternal exposure to tobacco smoke on the feto-placental unit. Early Hum Dev 2007; 83 (11) 699-706
• 11 Miller HC, Hassanein K, Hensleigh PA. Fetal growth retardation in relation to maternal smoking and weight gain in pregnancy. Am J Obstet Gynecol 1976; 125 (1) 55-60
• 12 Shiono PH, Klebanoff MA, Rhoads GG. Smoking and drinking during pregnancy. Their effects on preterm birth. JAMA 1986; 255 (1) 82-84
• 13 Jacobsen LK, Picciotto MR, Heath CJ , et al. Prenatal and adolescent exposure to tobacco smoke modulates the development of white matter microstructure. J Neurosci 2007; 27 (49) 13491-13498
• 14 Froeliger B, Kozink RV, Rose JE, Behm FM, Salley AN, McClernon FJ. Hippocampal and striatal gray matter volume are associated with a smoking cessation treatment outcome: results of an exploratory voxel-based morphometric analysis. Psychopharmacology (Berl) 2010; 210 (4) 577-583
• 15 Tsuang D, Larson EB, Li G , et al. Association between lifetime cigarette smoking and lewy body accumulation. Brain Pathol 2010; 20 (2) 412-418
• 16 Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology 2009; 73 (20) 1693-1698
• 17 Garshick E, Kelley A, Cohen SA , et al. A prospective assessment of mortality in chronic spinal cord injury. Spinal Cord 2005; 43 (7) 408-416
• 18 Krause JS, Carter RE, Pickelsimer E. Behavioral risk factors of mortality after spinal cord injury. Arch Phys Med Rehabil 2009; 90 (1) 95-101
• 19 Brown CW, Orme TJ, Richardson HD. The rate of pseudarthrosis (surgical nonunion) in patients who are smokers and patients who are nonsmokers: a comparison study. Spine 1986; 11 (9) 942-943
• 20 Liu PY, Lin CC, Tsai WC , et al. Treatment with dextromethorphan improves endothelial function, inflammation and oxidative stress in male heavy smokers. J Thromb Haemost 2008; 6 (10) 1685-1692
• 21 Booyse FM, Osikowicz G, Quarfoot AJ. Effects of chronic oral consumption of nicotine on the rabbit aortic endothelium. Am J Pathol 1981; 102 (2) 229-238
• 22 Kimura M, Higashi Y, Hara K , et al. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension 2003; 41 (5) 1106-1110
• 23 Tutka P, Mosiewicz J, Wielosz M. Pharmacokinetics and metabolism of nicotine. Pharmacol Rep 2005; 57 (2) 143-153
• 24 Vainio PJ, Tuominen RK. Cotinine binding to nicotinic acetylcholine receptors in bovine chromaffin cell and rat brain membranes. Nicotine Tob Res 2001; 3 (2) 177-182
• 25 Newman MB, Arendash GW, Shytle RD, Bickford PC, Tighe T, Sanberg PR. Nicotine's oxidative and antioxidant properties in CNS. Life Sci 2002; 71 (24) 2807-2820
• 26 Abreu-Villaça Y, Seidler FJ, Tate CA, Slotkin TA. Nicotine is a neurotoxin in the adolescent brain: critical periods, patterns of exposure, regional selectivity, and dose thresholds for macromolecular alterations. Brain Res 2003; 979 (1–2) 114-128
• 27 Helen A, Krishnakumar K, Vijayammal PL, Augusti KT. A comparative study of antioxidants S-allyl cysteine sulfoxide and vitamin E on the damages induced by nicotine in rats. Pharmacology 2003; 67 (3) 113-117
• 28 Sener G, Ozer Sehirli A, Ipçi Y , et al. Taurine treatment protects against chronic nicotine-induced oxidative changes. Fundam Clin Pharmacol 2005; 19 (2) 155-164
• 29 Rossignol S, Schwab M, Schwartz M, Fehlings MG. Spinal cord injury: time to move?. J Neurosci 2007; 27 (44) 11782-11792
• 30 Papadopolou S, Hartmann P, Lips KS, Kummer W, Haberberger RV. Nicotinic receptor mediated stimulation of NO-generation in neurons of rat thoracic dorsal root ganglia. Neurosci Lett 2004; 361 (1–3) 32-35
• 31 Lee MY, Chen L, Toborek M. Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury. J Neurosci Res 2009; 87 (4) 937-947
• 32 Osuka K, Watanabe Y, Takagi T , et al. Activation of endothelial nitric oxide synthase following spinal cord injury in mice. Neurosci Lett 2008; 436 (2) 265-268
• 33 Toborek M, Son KW, Pudelko A, King-Pospisil K, Wylegala E, Malecki A. ERK 1/2 signaling pathway is involved in nicotine-mediated neuroprotection in spinal cord neurons. J Cell Biochem 2007; 100 (2) 279-292
• 34 Weruaga E, Balkan B, Koylu EO, Pogun S, Alonso JR. Effects of chronic nicotine administration on nitric oxide synthase expression and activity in rat brain. J Neurosci Res 2002; 67 (5) 689-697
• 35 Marin VP, Pytynia KB, Langstein HN, Dahlstrom KR, Wei Q, Sturgis EM. Serum cotinine concentration and wound complications in head and neck reconstruction. Plast Reconstr Surg 2008; 121 (2) 451-457
• 36 Kasimatis GB, Panagiotopoulos E, Megas P , et al. The adult spinal cord injury without radiographic abnormalities syndrome: magnetic resonance imaging and clinical findings in adults with spinal cord injuries having normal radiographs and computed tomography studies. J Trauma 2008; 65 (1) 86-93
• 37 Cordero-Erausquin M, Pons S, Faure P, Changeux JP. Nicotine differentially activates inhibitory and excitatory neurons in the dorsal spinal cord. Pain 2004; 109 (3) 308-318
• 38 Damaj MI. Nicotinic regulation of calcium/calmodulin-dependent protein kinase II activation in the spinal cord. J Pharmacol Exp Ther 2007; 320 (1) 244-249
• 39 Zhao Z, Reece EA. Nicotine-induced embryonic malformations mediated by apoptosis from increasing intracellular calcium and oxidative stress. Birth Defects Res B Dev Reprod Toxicol 2005; 74 (5) 383-391
• 40 Ates O, Cayli SR, Gurses I , et al. Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. J Clin Neurosci 2007; 14 (7) 658-665
• 41 Dalgiç A, Armağan E, Helvacioğlu F , et al. High dose cotinine may induce neural tube defects in a chick embryo model. Turk Neurosurg 2009; 19 (3) 224-229
• 42 Duncan JR, Randall LL, Belliveau RA , et al. The effect of maternal smoking and drinking during pregnancy upon (3)H-nicotine receptor brainstem binding in infants dying of the sudden infant death syndrome: initial observations in a high risk population. Brain Pathol 2008; 18 (1) 21-31
• 43 Lavezzi AM, Corna MF, Matturri L. Ependymal alterations in sudden intrauterine unexplained death and sudden infant death syndrome: possible primary consequence of prenatal exposure to cigarette smoking. Neural Dev 2010; 5: 17
• 44 Malkawi AH, Al-Ghananeem AM, de Leon J, Crooks PA. Nicotine exposure can be detected in cerebrospinal fluid of active and passive smokers. J Pharm Biomed Anal 2009; 49 (1) 129-132
• 45 Bajanowski T, Brinkmann B, Mitchell EA , et al; GeSID Group. Nicotine and cotinine in infants dying from sudden infant death syndrome. Int J Legal Med 2008; 122 (1) 23-28
• 46 Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 1997; 20 (12) 570-577
• 47 Wanner IB, Deik A, Torres M , et al. A new in vitro model of the glial scar inhibits axon growth. Glia 2008; 56 (15) 1691-1709
• 48 Tran MD, Neary JT. Purinergic signaling induces thrombospondin-1 expression in astrocytes. Proc Natl Acad Sci U S A 2006; 103 (24) 9321-9326
• 49 Franklin RJM. Why does remyelination fail in multiple sclerosis?. Nat Rev Neurosci 2002; 3 (9) 705-714
• 50 Lee J, Gravel M, Zhang R, Thibault P, Braun PE. Process outgrowth in oligodendrocytes is mediated by CNP, a novel microtubule assembly myelin protein. J Cell Biol 2005; 170 (4) 661-673
• 51 Scherer SS, Braun PE, Grinspan J, Collarini E, Wang DY, Kamholz J. Differential regulation of the 2′,3′-cyclic nucleotide 3′-phosphodiesterase gene during oligodendrocyte development. Neuron 1994; 12 (6) 1363-1375